Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$4.66 - $10.31 $81,107 - $179,445
17,405 New
17,405 $84,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $137M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Apogem Capital LLC Portfolio

Follow Apogem Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Apogem Capital LLC with notifications on news.